克服闭环系统限制:稀释胰岛素改善血糖控制,减少夜间低血糖在婴幼儿与低胰岛素需求的婴儿
Olivier G Pollé1,2, Gaëlle Vermillac2, Robin Fortier3
1Pediatric Diabetology and Endocrinology Unit, CHU Namur, Université Catholique de Louvain, Yvoir, Belgium.
Diabetes technology & therapeutics
|January 23, 2026
概括
使用混合闭环系统 (HCL) 的胰岛素稀释改善了1型糖尿病 (T1D) 的幼儿的葡萄糖控制. 这种安全有效的策略减少了葡萄糖的变化和警报,提高了范围内的时间,以更好地管理糖尿病.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 代谢疾病 代谢疾病
- 生物医学工程 生物医学工程
背景情况:
- 患有1型糖尿病 (T1D) 的非常小的儿童经常经历低于最佳的血糖控制,即使使用先进的混合闭环 (HCL) 系统,特别是那些总日用胰岛素剂量 (TDD) 较低的系统.
- 实现目标血糖指标的挑战需要探索替代策略,以优化这种脆弱人群中的糖尿病管理.
研究的目的:
- 用HCL系统评估使用稀释胰岛素配方对T1D非常年幼儿童的葡萄糖控制的影响.
- 评估胰岛素稀释作为辅助治疗的安全性和有效性,以改善TDD低的儿科T1D患者的血糖结果.
主要方法:
- 这是一项回顾性多中心研究,涉及35名6岁以下患有T1D的儿童,使用CamAPS FX HCL系统.
- 参与者从标准U100胰岛素转换为稀释胰岛素 (U10,U20或U50).
- 持续血糖监测 (CGM) 数据和临床结果在稀释前和后 (1,3,6个月) 使用线性混合模型进行了分析.
主要成果:
- 胰岛素稀释与时间低于范围 (TBR70) 的显著减少有关,特别是在一夜之间,并且降低了葡萄糖可变性 (变化系数).
- 每天观察到范围内的时间 (TIR70-180) 显著增加1.5小时,范围以上的时间 (TAR180) 减少1小时.
- 没有发生严重的低血糖或糖尿病酸事件,这表明稀释胰岛素使用的安全性是有利的.
结论:
- 胰岛素稀释是一种安全有效的策略,用于使用HCL系统改善T1D和低TDD的非常年幼儿童的葡萄糖控制.
- 这种干预提供了一种实际的解决方案,以提高血糖管理,并减少与糖尿病相关的并发症在患有低于最佳控制的儿科患者群体.
相关概念视频
Open and closed-loop control systems
1.6K
Control systems are foundational elements in automation and engineering. They are broadly categorized into open-loop and closed-loop systems. These classifications hinge on the presence or absence of feedback mechanisms, significantly influencing the system's performance, complexity, and application.
An open-loop control system operates without feedback from the output. It consists of two primary elements: the controller and the controlled process. The controller receives an input signal...
An open-loop control system operates without feedback from the output. It consists of two primary elements: the controller and the controlled process. The controller receives an input signal...
1.6K
Insulin Secretory Vesicles
6.4K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.4K
Insulin: The Receptor and Signaling Pathways
2.9K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.9K
Insulin Formulations: Types and Delivery
676
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
676
Insulin: Biosynthesis, Chemistry, and Preparation
1.3K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.3K
Insulin: Dosing Regimen and Adverse Effects
711
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
711


